
Zongertinib: A New Precision Standard for HER2-Mutant Lung Cancer
Zongertinib shows high efficacy as a first-line treatment for HER2-mutant non-small-cell lung cancer. The drug offers a 76% response rate while minimising side effects by sparing healthy cells.
By Heymach, Yamamoto, Girard, Ruiter, Smit, Planchard, Nadal, Wu, Zugazagoitia, Tu, Baik, Yoh, Soo, Zhao, Sabari, Wermke, Scheffler, Ahn, Fernamberg, Schroeter, Sadrolhefazi, Thamer, Eigenbrod-Giese, Popat

